Table 1. Summary of vectors, pathogens, organs involved and diseases in some common vector-borne protozoan illnesses of potential neurological interest.

Vector	Pathogen	Human organs involved	Disease
Tse tse fly	Trypanosoma brucei gambiense, T. brucei rhodesiense	Brain, peripheral nerves, heart, liver, spleen, kidneys, skin, eyes	Human African Trypanosomiasis
Bugs: Triatoma, Rhodnius	Trypanosoma cruzi	Heart, oesophagus, colon	Chagas disease
Sand fly: Phlebotomus, Lutzomyia	Leishmania	Skin, spleen, liver, bone marrow, lymph nodes	Leishmaniasis
Ticks: Ixodes	Babesia	Blood, bone marrow, spleen, liver	Babesosis
Mosquito: Anopheles	Plasmodium falciparum, P.vivax	RBC, spleen, liver, brain	Malaria

Table 2. Treatment options in various vector-borne protozoan diseases

Cerebral malaria

Anti-infective treatment:

Adults and children> 20 kg weight with severe malaria: Intravenous or intramuscular artesunate, 2.4 mg/kg/dose for 24 hours or till oral treatment is feasible. Thereafter oral treatment with any available artesunate-based combination treatment should be continued for three days.

Pregnant women and lactating mothers: as above

Individuals with clinical renal or hepatic impairment: as above

Children < 20 kg weight: Intravenous or intramuscular artesunate, 3.0 mg/kg/dose for 24 hours or till oral treatment is feasible.

When parenteral artesunate is not available: Intramuscular artemether, 3.2 mg/kg/dose in the first 24 hours, followed by 1.6 mg/kg/day for 3 days OR

Intravenous quinine, 20 mg salt/kg, diluted in 5% dextrose and administered slowly over 4 hours, followed by 10 mg salt/kg, Q8 hours

Management of complications:

Coma: Airway protection and intubation; nasogastric tube insertion and toilet; Rule out hypoglycaemia; Nurse on sides; Keep in intensive care Convulsive seizures or status epilepticus: Airway protection and intubation; Intravenous benzodiazepenes (resort to rectal use may be considered in children) in standard dose used to treat status epilepticus followed the standard protocol-based treatment of status epilepticus.

Hypoglycemia: Frequently monitor blood glucose; maintain Dextrose infusions

Coagulopathy: Fresh frozen plasma, Cryoprecipitate, Platelet transfusion; Parenteral Vitamin K

Anaemia: Fresh whole blood transfusion

Human African Trypanosomiasis

Stage 1: CSF WBC ≤ 5/µL

T. b. gambiense:

Oral Fexinidazole 1200 mg (children*) or 1800 mg (adults*) loading for 4 days followed by 600 (children) or 1200 mg/day (adults) for 6 days OR

IM Pentamidine 4 mg/kg intramuscular for 7 days**

T. b. rhodesiense:

IV Suramin, 5 mg/kg by slow intravenous infusion on day 1, 10 mg/kg on day 3, and then 20 mg/kg on days 5, 11, 17, 23, and 30, to a maximum cumulative dose of 10 g.

Stage 2:

T. b. gambiense:

Cerebrospinal fluid WBC count < 100/µL

Oral Fexinidazole 1200 mg (children*) or 1800 mg (adults*) loading for 4 days followed by 600 (children) or 1200 mg/day (adults) for 6 days OR

NECT (nifurtimox-eflornithine combination therapy) as first line treatment***: Nifurtimox 5 mg/kg/8h PO for 10 days;

Singh et al. Vector-borne protozoal disorders; Tables

Eflornithine 200mg/kg/12h IV in 2-h infusion (each diluted in 250 mL of water) for 7 days

XX serious omission!!!

T. b. rhodesiense:

IV Melarsoprol 2.2mg/kg per day for 10 days as first line treatment

Commented [PN1]: Cerebrospinal fluid WBC count > 100/uL (severe second stage)

NECT (nifurtimox-eflornithine combination therapy) as first line treatment

IV Melarsoprol 2.2mg/kg per day for 10 days (slow injection) as second line $\,$

Commented [GS2R1]: Sorry Alfred, I am not clear, whether the above is to be included in the table or not? Please advise.

Commented [PN3]: It is important to include the above for severe stage 2 gambiense disease!